What happens when you do everything "right" — the GLP-1, the protein shake, the tracking — and the scale still won't budge? This episode reveals why doing everything “right” might actually be a big part of the problem.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor welcome Sandy, a listener from Pennsylvania who has been on the metabolic health journey for over a year. Sandy's story is one many listeners will recognize: decades of dieting starting in childhood, a body that kept adapting against her, and a medical system that kept telling her to try harder. But when Dr. Cooper reviews Sandy's actual lab work live on air, what she finds reframes everything — and offers a path forward that has nothing to do with restriction.

Key Takeaways

• Suppressed leptin hides a portion of your body fat from your brain, and possibly signals your brain that you're underweight — so your brain fights weight loss even when your body doesn't need protecting.

• Low insulin isn't always healthy; it can be a sign of the "selfish brain" redirecting precious glucose to the brain at the expense of your muscles.

• Weight cycling — losing and regaining the same weight repeatedly — creates cardiovascular and metabolic risk.

• Mechanical eating is the antidote to disordered eating: structured, non-restrictive fueling that rebuilds metabolic trust.

• GLP-1 medications can suppress appetite, so under-eating becomes a real risk — especially for people already conditioned to restrict.

• The goal isn't the number on the scale. It's metabolic stability and metabolic health, and those things are not the same.

Notable Quote

"It was such a revelation to me to hear you guys talk about it — it's a metabolic disorder. It's not a willpower issue, it's not a personal failing. It's something absolutely beyond my control. Like diabetes would be. Like migraines would be." — Sandy

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)

What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.

Key Takeaways

• Oral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.

• The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.

• Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”

• Pricing and access shape who can actually benefit, even when the science is strong.

• Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.

Notable Quote

"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark Wright

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Mailbag: Your GLP-1 Questions on Pregnancy, Dosing, and Why Diets Cause Fat Gain

What happens when you stop GLP-1 medications before getting pregnant? Why might your thyroid numbers change on Zepbound? And why do people gain more body fat after dieting — even when they're still eating well? Dr. Cooper tackles your toughest questions.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions covering pregnancy planning on GLP-1s, unmasked thyroid problems, injection site reactions, mechanical eating after bariatric surgery, why diets cause fat regain at a cellular level, and discussing with your doctor whether you should (or shouldn't) increase your medication dose.

Key Takeaways

• GLP-1 medications aren't causing gestational diabetes — they may have been masking underlying metabolic dysfunction that becomes visible when the medication is stopped

• Thyroid problems can be "unmasked" by GLP-1 treatment because the medications signal to your brain that you're not starving, allowing the pituitary TSH to rise, sometime uncovering a pre-existing thyroid issue

• Zepbound may improve iron absorption — if iron levels go too high, testing for hemochromatosis may be warranted

• To reduce injection site reactions: warm the medication to room temperature, clean and prep skin but don't over-rub with alcohol, inject at exactly 90 degrees, don't pinch the skin, and stay relaxed

• Diets cause fat regain at the cellular level — it's chemistry, not willpower — and the fat often accumulates in the visceral area around organs

• There's no need to increase your GLP-1 dose if you're making good progress — an annual weight loss rate of 15% or higher is considered strong

Notable Quote

"You can't think that just because somebody's weight is high, it's because something they're doing is wrong. That is just not founded in science whatsoever." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Wegovy Pill: Who's It For?

The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.

Key Takeaways

• The Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as Rybelsus

• Semaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular risk

• The pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectiveness

• The pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum dose

• Novo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest dose

• Eli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritual

Notable Quote

"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What if the scale isn't moving, but your health is dramatically improving?

If you've ever felt discouraged because the number on the scale won't budge—even on a GLP-1 medication—this episode will change how you think about these drugs. Dr. Cooper breaks down the research showing that the biggest benefits have nothing to do with weight loss. It's all about metabolic health.

This Week on Fat Science

Dr. Emily Cooper, Mark Wright, and Andrea Taylor explore the research proving GLP-1 medications are far more than "weight loss drugs." The team explains how cardiovascular outcome trials revealed unexpected heart protection, why inflammation reduction may be the real mechanism behind these benefits, and what the latest FDA approvals for kidney disease, sleep apnea, and fatty liver mean for patients. Plus: the new oral Wegovy pill, what's coming next in metabolic medicine, and why everyone should be screened for metabolic dysfunction regardless of weight.

What You'll Learn

• Why two-thirds of cardiovascular risk reduction from GLP-1s is completely independent of weight loss

• How these medications reduce inflammation, stabilize arterial plaque, and improve vascular function

• The difference between MASLD and MASH—and why the name change matters

• What the Flow Trial revealed about kidney protection (and why it was stopped early)

• How Zepbound earned FDA approval for sleep apnea

• Why metabolic screening should happen regardless of what the scale says

Notable Quote

"You can still become incredibly healthier even if the weight is more stubborn. So I think that's the thing, is to discuss with your doctor not 'Oh, I want to lose X amount of pounds' or 'How much weight do you think I should lose?' That is not the conversation. It's more, let's take a look at the health parameters."

— Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions from California, the UK, France, Washington, Wyoming, and beyond. 

The team breaks down why Dr. Cooper does not recommend calorie tracking (and when limited tracking can make sense), how to build confidence in eating without data, and why “mechanical eating” sometimes needs medical customization—especially for people with slow gut transit or gastroparesis-like symptoms. 

They also dig into bile acid malabsorption after gallbladder removal, when metformin side effects deserve a second look, what we currently know about COVID-19’s potential impact on metabolic health, and why metformin and GLP-1 medications can be complementary—particularly in PCOS.

Key Takeaways
• Long-term calorie tracking can override physiologic cues and reinforce diet mentality.
• Short-term, targeted tracking may be useful when guided by a clinician (e.g., nutrient deficiencies ).
• Obesity and abnormal appetite are both manifestations of metabolic dysfunction—not simple cause and effect.
• Mechanical eating is a framework, not a rigid rule—timing and food choices may need medical tailoring.
• Post-gallbladder diarrhea may reflect bile acid malabsorption and can be treatable.
• Metformin and GLP-1s often complement each other because they target different metabolic states (fasting vs fed).

Dr. Cooper’s Actionable Tips
• Stop daily calorie counting—focus on consistent patterns and metabolic nourishment.
• Use mechanical eating basics: eat every few hours, include all food groups, and reduce chemical additives when possible.
• If you’re transitioning away from tracking, consider a dietitian skilled in diet-mentality recovery.
• If frequent eating worsens sleep or bloating, work with a medical dietitian to adjust intervals and food types (especially with slow GI transit).
• If chronic diarrhea appears (especially after gallbladder removal), ask your clinician about bile acid malabsorption and treatment options.
• Use labs to guide therapy: fasting insulin can signal metformin benefit; post-meal patterns can point toward GLP-1 needs.

Notable Quote
“Once you start using tracking to stay in a calorie range or a carbohydrate range, you’re putting your brain in front of your physiologic intuition—your body is sending you important cues all the time.”
—Dr. Emily Cooper

Links & Resources

The Metabolic Links to PCOS, Release Date 2/24/25

The COVID Connection to Diabetes & Metabolic Health, Release Date 12/16/24

Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: [email protected]

*Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

his week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions that get to the heart of metabolic health. The team explains the real difference between meals and snacks, discusses whether GLP-1 medications can be appropriate for children in complex cases, explores why some people appear to be “non-responders” to Wegovy, and breaks down why alarming headlines about rapid weight regain miss the bigger metabolic picture. They also explain how to set a goal weight using body composition, labs, and overall health—rather than the scale alone.

Key Questions Answered
• What separates a meal from a snack metabolically?
• Why can grazing all day backfire—even with healthy food?
• Are GLP-1s ever appropriate for kids?
• Why do some people feel hungrier as GLP-1 doses increase?
• How are PCOS and insulin dysregulation connected?
• What is a mixed meal tolerance test, and why does it matter?
• Do GLP-1 users really regain weight faster?
• How should goal weight be determined after major weight loss?

Key Takeaways
• Meals provide structure; snacks prevent long gaps—both matter.
• GLP-1 “non-response” often signals deeper metabolic issues.
• Weight regain reflects underlying dysfunction, not personal failure.
• Maintenance dosing must be individualized.
• Body composition matters more than BMI or scale weight.

Dr. Cooper’s Actionable Tips
• Eat structured meals with carbs, protein, and fats.
• Use snacks strategically to avoid long gaps.
• Ask about deeper glucose/insulin testing when progress stalls.
• Prioritize DEXA body composition over scale-based goals.
• Avoid compounded GLP-1s—especially in children.

Notable Quote

“If you stop treating the metabolic dysfunction, the dysfunction is still there—and the body will drive weight back to where it was headed all along.”
—Dr. Emily Cooper

Links & Resources
Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: [email protected]

Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down two GLP-1 studies that challenge a major media myth: GLP-1 medications don’t drive weight loss just because people eat less. Instead, drugs like tirzepatide and semaglutide create direct metabolic shifts—including increased fat oxidation and improved fuel partitioning—regardless of appetite.

The team also explores mechanical eating, the psychological impact of “diet food,” and Andrea’s 13-year metabolic recovery journey.

Key Questions Answered

• If both groups are dieting, why does the tirzepatide group lose more weight?
• What is metabolic adaptation, and why does dieting slow metabolism so sharply?
• How do GLP-1s directly increase fat oxidation?
• What is mechanical eating, and why do GLP-1 users need it?
• Why does ad-lib eating produce different metabolic responses than calorie restriction?
• Can mindset alone change hunger hormones? (Yes—the milkshake study.)
• Why do diet foods and diet sodas fail to improve metabolic health?
• Why is response to GLP-1s so different from person to person?

Key Takeaways

• GLP-1s are metabolic drugs—not appetite suppressants.
  Their power comes from hormonal effects on fat burning, not reduced food intake.
• Calorie restriction still slows metabolism.
  Even on GLP-1s, dieting triggers significant metabolic slowdown.
• Ad-lib eating outperforms dieting in the research.
  Semaglutide users who ate freely did not show the extra metabolic slowdown seen in dieters.
• Mechanical eating is the most durable long-term approach.
  Regular meals and snacks protect lean mass and prevent famine signaling.
• Mindset shapes hormones.
  Believing a food is “diet” vs. “indulgent” alters ghrelin and satisfaction.
• Track body composition—not just the scale.
  DEXA scans show whether you’re losing fat, muscle, or bone.

Dr. Cooper’s Actionable Tips

• Don’t diet on GLP-1s. Focus on fueling, not restriction.
• Use mechanical eating: predictable meals and snacks, no long gaps.
• Prioritize satisfaction: diet foods often backfire hormonally.
• Follow your real-world data: long-term changes matter more than short-term scale shifts.
• Ask about body composition testing if possible.

Notable Quote:

“What that study proved is that doing the calorie restriction is causing the metabolic slowing… and that’s why it’s so confusing to me that we keep advising people to restrict calories when they’re trying to improve their metabolic function.” —Dr. Emily Cooper

Links & Resources

Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: [email protected]
Dr. Cooper Email: [email protected]

Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational only, and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle a wide-ranging mailbag episode with listener questions from the U.S., UK, and Europe. Topics include unexpected weight regain on GLP-1s, post-meal sleepiness and hypoglycemia, metabolic dysfunction despite normal labs, GLP-1 dosing strategies, and why these medications are about metabolism, not appetite suppression.

Key Questions Answered

• Why can weight regain happen on GLP-1s even when habits haven’t changed?
• How do leptin, ghrelin, injury, stress, and under-fueling affect weight regulation?
• What does it mean if you get extremely sleepy after meals—is it hypoglycemia?
• Do GLP-1s increase insulin in a harmful way for non-diabetics?
• Can you have metabolic dysfunction with normal A1C, cholesterol, and blood pressure?
• Do GLP-1 medications “wear off,” and how should dosing be adjusted long term?
• Are GLP-1s just appetite suppressants—or true metabolic treatment?
• Is it possible to undo decades of calorie counting and restriction-based thinking?
• What are the risks of the return to extreme thinness in celebrity culture?

Key Takeaways

• Calories don’t explain metabolism. GLP-1 and GIP work across the brain and body—repairing signaling, not just reducing appetite.
• Leptin matters after dieting. Years of restriction and weight cycling can weaken leptin signaling, making the brain defend weight gain.
• Fueling is foundational. Medication can’t replace adequate food, sleep, and recovery.
• Post-meal fatigue is a clue. Reactive hypoglycemia is common and often misunderstood.
• Lowest effective dose wins. GLP-1 success is about pacing, not racing to the max dose.
• Chasing the “last 10 pounds” can backfire. Cosmetic restriction can create new metabolic problems.

Dr. Cooper’s Actionable Tips

• If weight gain appears after injury or stress, focus first on sleep, regular meals, and full fueling, not restriction.
• Suspected hypoglycemia? Ask about a mixed meal tolerance test to assess glucose and insulin response.
• Stay on the lowest GLP-1 dose that’s working and adjust only when progress truly stalls.
• Push back on “appetite suppressant” language—these meds amplify hormones your body already makes.

Notable Quote

“GLP-1s aren’t about eating less—they’re about strengthening metabolic signaling” — Dr. Emily Cooper

Links & Resources

Podcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/

Podcast Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Show Question: [email protected]
Dr. Cooper direct show email: [email protected]

Fat Science breaks diet myths and advances the science of real metabolic health. No diets, no agendas—just science that makes you feel better. This show is informational only and does not constitute medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with pediatric eating disorder specialist Dr. Julie O’Toole (Kartini Clinic) and pediatric obesity expert Dr. Evan Nadler about what childhood obesity really is: a biologic, metabolic disease—not a willpower problem and not a failure of parenting.

They explore how excess weight, constant hunger, and disordered eating in kids are often signs of underlying metabolic dysfunction and genetics—and why the old “eat less, move more” advice can do real harm, especially when children are shamed or restricted in the name of “health.”

Key Questions Answered

• Why is childhood obesity a metabolic disease, not a behavior problem?
• How are obesity and eating disorders deeply connected instead of opposite extremes?
• What role do GLP-1 medications play in children—and how do we protect against under-fueling?
• When should parents suspect genetic drivers like hyperphagia or MC4 mutations?
• How can medical treatment for obesity actually reduce disordered eating behaviors?
• When does excess weight become a medical issue requiring metabolic evaluation—not another diet?

Key Takeaways

• Weight is a symptom. Childhood obesity is often a sign of metabolic dysfunction, not overeating.
• Obesity & eating disorders overlap. Restriction can trigger disordered eating; disordered eating can worsen obesity.
• “Eat less, move more” harms. Shame-based approaches delay treatment and increase risk of eating disorders.
• GLP-1s work metabolically, not just through appetite suppression. Kids still need consistent fueling.
• Genetics matter. Single-gene differences can drive severe childhood hunger & rapid weight gain.
• Not treating is harm. Avoiding obesity care violates first, do no harm.

Dr. Cooper’s Actionable Tips

• If your child is gaining weight or constantly hungry, request metabolic labs (insulin, glucose, lipids, liver, hormones).
• If the doctor only says “eat less, move more,” ask: “How are we evaluating metabolism and genetics?”
• On GLP-1s? Monitor for under-fueling (skipped meals, low energy, food anxiety) and intervene promptly.

Notable Quote

“Not treating childhood obesity is doing harm. It’s a disease, not a lifestyle choice.” — Dr. Evan Nadler

Links & Resources

• Podcast Home: Fat Science Website
• Episodes & Show Archive: Cooper Center Podcast Page
• Education & Metabolic Resources: coopermetabolic.com/resources
• Submit a Show Question: [email protected]
• Email Dr. Cooper Directly: [email protected]

Connect with Our Guests

Dr. Evan P. Nadler, MD, MBA – Founder, ProCare Consultants & ProCare TeleHealth
Website: obesityexplained.com
YouTube Channel: Obesity Explained

Dr. Julie K. O’Toole, M.D., M.P.H. – Chief Medical Officer & Founder, Kartini Clinic
Website: kartiniclinic.com
Books: amazon.com/author/julieotoole

*Fat Science breaks diet myths and advances the science of real metabolic health. No diets. No agendas. Just science that makes you feel better. This episode is informational only and not medical advice.